Article
In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor.
Antimicrobial agents and chemotherapy - 1 Nov 2013
Voitenleitner Christian, Crosby Renae, Walker Jill, Remlinger Katja, Vamathevan Jessica, Wang Amy, You Shihyun, Johnson John, Woldu Ermias, Van Horn Stephanie, Horton Joseph, Creech Katrina, Shotwell J Brad, Hong Zhi, Hamatake Robert
Abstract excerpt
GSK2485852 (referred to here as GSK5852) is a hepatitis C virus (HCV) NS5B polymerase inhibitor with 50% effective concentrations (EC50s) in the low nanomolar range in the genotype 1 and 2 subgenomic replicon system as well as the infectious HCV cell culture system. We have characterized the antiviral activity of GSK5852 using chimeric replicon systems with NS5B genes from additional genotypes as well as NS5B...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
